UBS Maintains Neutral on Stevanato Group, Lowers Price Target to $23
UBS analyst Dan Leonard maintains Stevanato Group (NYSE:STVN) with a Neutral and lowers the price target from $28 to $23.
Stocks · News reference
Stevanato Group Says Liraglutide-Based Combination Products Incorporating Its Proprietary Alina Pen Injector Platform Receives Marketing Authorizations In Europe
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Stevanato Group Q2 2026 Earnings Call: Complete Transcript
Stevanato Group (NYSE:STVN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
Stevanato Group Lowers FY2026 GAAP EPS Guidance from $0.64-$0.69 to $0.62-$0.64; Lowers FY2026 Sales Guidance from $1.467B-$1.500B to $1.465B-$1.488B
Stevanato Group (NYSE:STVN) lowers FY2026 GAAP EPS guidance from $0.64-$0.69 to $0.62-$0.64. Lowers FY2026 sales outlook from $1.467 billion-$1.500 billion to $1.465 billion-$1.488 billion.
Stevanato Group Narrows FY2026 Adj EPS Guidance from $0.69-$0.73 to $0.70-$0.72 vs $0.68 Est; Lowers FY2026 Sales Guidance from $1.467B-$1.500B to $1.465B-$1.488B vs $1.500B Est
Stevanato Group (NYSE:STVN) narrows FY2026 Adj EPS guidance from $0.69-$0.73 to $0.70-$0.72 vs $0.68 analyst estimate. Lowers FY2026 sales outlook from $1.467 billion-$1.500 billion to $1.465 billion-$1.488 billion vs